Evaluation of Serum- and OCT Biomarkers in Patients With DME Treated With Anti-VEGF or Dexamethasone Implant
Recruiting
N/A
Interventional Study
Diabetic Macular Edema
Visual Impairment
Diabetes Mellitus
Hyperglycaemia (Diabetic)
Oxidative Stress
Vascular Endothelial Growth Factor
VEGF
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Prevention
- Participants needed
- 150 (estimated)
- Sponsor
- Vastra Gotaland Region · Government
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study aims to investigate the association between serum biomarkers and clinical response to anti-VEGF or dexamethasone implant by assessing OCT-biomarkers in patients with diabetic macular edema, DME, and to compare these with a group of naive patients (those not previously treated for DME).
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Type I or type II DM.
* DME involving the center of the fovea with CFT more than 280 microns and the presence of intraretinal cysts.
Exclusion Criteria:
* Prior history of any other macular disease.
* Previous treatment with dexamethasone implants in the last six months for …
Contacts